Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | HTR7 | P34969 | 3/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295235 | 0.93 | CCR1 (0.33) | CCR1CCR5 | |
| SCHEMBL3441650 | 0.89 | CCR5 (0.34) | CCR1CCR5ALDH1A1AKR1C3 | |
| SCHEMBL3441647 | 0.89 | CCR5 (0.34) | CCR1CCR5ALDH1A1AKR1C3 | |
| SCHEMBL4300734 | 0.88 | BDKRB1 (0.40) | — | |
| SCHEMBL3441640 | 0.83 | BDKRB1 (0.39) | HTR7ALDH1A1 | |
| SCHEMBL3441641 | 0.83 | BDKRB1 (0.39) | HTR7ALDH1A1 | |
| SCHEMBL4295145 | 0.83 | BDKRB1 (0.36) | CCR1RORC | |
| SCHEMBL4299091 | 0.82 | ALDH1A1 (0.35) | CCR1CCR5DRD2HTR7DRD3 | |
| SCHEMBL3441731 | 0.82 | BDKRB1 (0.39) | HTR7 | |
| SCHEMBL4290344 | 0.80 | BDKRB1 (0.40) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264400-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | CCR1 637/4885CCR5 1354/4885DRD2 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.